# Autem Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/autem-therapeutics

- Industry: Medical Devices & Equipment
- Headquarters: Hanover, US
- Website: www.autemtherapeutics.com
- Total disclosed funding: $10M
- Latest round: Series A (Jun 6, 2022)
- Investors on record: 1

## About

Based in New Hampshire, US, and founded in 2017 by CEO Michael Choukas, and CSO Frederico Costa, Autem Therapeutics LLC is developing a novel bioelectric oncology treatment platform to deliver low-level, amplitude-modulated electromagnetic (EM) frequency for the treatment of hepatocellular carcinoma (HCC) and other solid tumor cancers. In June 2022, Autem Therapeutics raised USD 10 million in a Series A funding led by Zentynel Frontier Investments. As of July 2022, Michael Choukas is the CEO of Autem Therapeutics.

The company provides AutEMsys, a therapy that delivers personalized, amplitude-modulated electromagnetic (EM) frequencies to patients systemically to shrink tumors as well as enhance the quality of life and extend survival in early and advanced stage patient populations.

Autem Therapeutics plans to use its proceeds from July 2022 funding for the completion of its technology and related validation and testing, approvals to initiate clinical trials, European and Latin American regulatory, and US FDA Investigational Device Exemption (IDE) submissions, and the start-up phase of the HCC pivotal trial.

## Funding rounds

- Series A, Jun 6, 2022, $10M — Zentynel Frontier Investments

## Investors

- Zentynel Frontier Investments (https://capitalatlas.ai/funds/zentynel-frontier-investments) — Series A